CIDARA THERAPEUTICS INC (CDTX) Stock Price, Forecast & Analysis
NASDAQ:CDTX • US1717572069
CDTX Key Statistics, Chart & Performance
The current stock price of CDTX is 221.38 USD. In the past month the price increased by 0.46%. In the past year, price increased by 822.42%.
CDTX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CDTX. When comparing the yearly performance of all stocks, CDTX is one of the better performing stocks in the market, outperforming 99.77% of all stocks.
CDTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CDTX. While CDTX has a great health rating, there are worries on its profitability.
CDTX Financial Highlights
Over the last trailing twelve months CDTX reported a non-GAAP Earnings per Share(EPS) of -11.78. The EPS decreased by -70.23% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -35.62% | ||
| ROE | -43.74% | ||
| Debt/Equity | 0 |
CDTX Forecast & Estimates
14 analysts have analysed CDTX and the average price target is 220.19 USD. This implies a price decrease of -0.54% is expected in the next year compared to the current price of 221.38.
For the next year, analysts expect an EPS growth of 27.77% and a revenue growth -100% for CDTX
CDTX Ownership
CDTX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.36 | 390.397B | ||
| AMGN | AMGEN INC | 16.32 | 197.396B | ||
| GILD | GILEAD SCIENCES INC | 17.35 | 193.298B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.78 | 117.026B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.93 | 81.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 46.33 | 42.576B | ||
| INSM | INSMED INC | N/A | 31.656B | ||
| NTRA | NATERA INC | N/A | 29.322B | ||
| BIIB | BIOGEN INC | 12.57 | 28.06B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.09 | 20.49B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CDTX
Company Profile
Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The firm is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
Company Info
CIDARA THERAPEUTICS INC
6310 Nancy Ridge Dr Ste 101
San Diego CALIFORNIA 92121 US
CEO: Jeffrey Stein
Employees: 69
Phone: 18587526170
CIDARA THERAPEUTICS INC / CDTX FAQ
What does CIDARA THERAPEUTICS INC do?
Cidara Therapeutics, Inc. engages in developing targeted immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The company is headquartered in San Diego, California. The company went IPO on 2015-04-15. The firm is using its Cloudbreak platform to develop drug-Fc conjugate (DFC), immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases. The Company’s Cloudbreak platform enables development of DFCs that inhibit specific disease targets while simultaneously engaging the immune system. The Company’s lead DFC candidate CD388, is a highly potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which has completed Phase I and Phase IIa clinical trials. Its oncology DFC candidate, CBO421, is a development candidate targeting CD73 for the treatment of solid tumors. Its Cloudbreak platform creates single molecule cocktails by coupling targeted small molecules and peptides to a human antibody fragment (Fc). The firm is also advancing multiple preclinical and discovery programs targeting cancer and autoimmune diseases.
What is the stock price of CIDARA THERAPEUTICS INC today?
The current stock price of CDTX is 221.38 USD. The price increased by 0.03% in the last trading session.
Does CIDARA THERAPEUTICS INC pay dividends?
CDTX does not pay a dividend.
What is the ChartMill rating of CIDARA THERAPEUTICS INC stock?
CDTX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for CDTX stock?
14 analysts have analysed CDTX and the average price target is 220.19 USD. This implies a price decrease of -0.54% is expected in the next year compared to the current price of 221.38.
What is the expected growth for CDTX stock?
The Revenue of CIDARA THERAPEUTICS INC (CDTX) is expected to decline by -100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of CDTX stock?
CIDARA THERAPEUTICS INC (CDTX) has a market capitalization of 6.96B USD. This makes CDTX a Mid Cap stock.